Hereditary Angioedema Therapeutics Market Research Report Information by Type (Type I, Type II), By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others), By Treatment (Prophylaxis - Long-term Prophylaxis, Short-term Prophylaxis, On-demand), By Route of Administration (Intravenous, Subcutaneous, Oral), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, Asia Pacific, Rest of the World) - Market Forecast Till 2032

Global Hereditary Angioedema Therapeutics Market Overview

The Hereditary Angioedema Therapeutics Market Size was valued at USD 4.8 billion in 2022 and is projected to grow from USD 5.7 billion in 2023 to USD 12.4 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 17.7% during the forecast period (2023 - 2032). The rising awareness about the earlier diagnosis and treatment of the disease across the globe and the increase in R&D investments are driving the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Hereditary Angioedema Therapeutics Market Trends

• Increasing awareness of HAE among the populations to boost the market growth

The increasing awareness of HAE among populations is a significant driver of market expansion. As per the Department of Health & Social Care, people are continuously aware of the hereditary angioedema disease and their effective treatment. The Health & Social Care Department of UK has worked with the four nations to confirm that hereditary angioedema disease patients receive better diagnosis and treatment care. In addition, many companies are also keenly interested in launching hereditary angioedema awareness programs. 

For instance: in May 2023 Takeda Biopharmaceuticals India launched the hereditary angioedema awareness program “Sunrise Patient Services Program (PSP)’ for Hereditary Angioedema (HAE) patients in India. This program aims to provide patient support on four main elements including screening & diagnosis, treatment, and maintenance support applied, quality diagnostic labs, treatment compensation navigation, and lifestyle counseling support during the patient’s treatment journey. 

Furthermore, In 16 May 2022, HAE Awareness Day was pragmatic across the globe to increase awareness about hereditary angioedema (HAE) and those patients the disorder affects. The aim is to raise awareness among the population as well as industry representatives, and healthcare professionals. With the help of this HAE Awareness Day developed an atmosphere for accurate and early diagnosis as well as improved HAE patient care, an Awareness Day webpage states. So that patients can get a better quality of life. 

The global HAE awareness efforts were being led by HAE International (HAEi), which is an international network of patient organizations that look to improve the quality of life of HA patients. At present time HAEi supports 93 member organizations across the globe. Thus rising awareness programmes by government and private institutions play a key role in early diagnosis and better therapeutics for hereditary angioedema disease of patients which is propel the market growth of the hereditary angioedema therapeutics.

Hereditary Angioedema Therapeutics Market Segment Insights:

Hereditary Angioedema Therapeutics Type Insights

The Market segments of Hereditary Angioedema Therapeutics, based on type, includes type I, type II . The type I segment held the majority share in 2022 in the Hereditary Angioedema Therapeutics Market revenue due to the rising prevalence of these HAE types. Patients with Type I and Type II HAE require different treatment strategies, leading to diverse therapeutic demands. .

BioCryst Pharmaceuticals Inc announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) implemented a positive opinion recommending the approval of ORLADEYO (Berotralstat) for routine prevention of repeated occurrences of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older.“

Hereditary Angioedema Therapeutics Drug Class Insights

The Hereditary Angioedema Therapeutics Market segmentation based on drug class includes C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Others. The C1 Esterase inhibitors segment dominated the market in 2022. As the demand for C1 Esterase Inhibitors remains strong as they are considered the standard of care for acute HAE attacks. These drugs are gaining popularity as oral medications for both prophylaxis and on-demand treatment, addressing the demand for alternative treatment options. Kallikrein inhibitors are emerging as a novel class of drugs with increasing demand due to their potential effectiveness in reducing HAE attacks.

Hereditary Angioedema Therapeutics Treatment Insights

The Market segmentation of Hereditary Angioedema Therapeutics based on treatment includes prophylaxis, On-demand. Prophylaxis segment dominated the market in 2022 due to the prophylactic treatments, including both long-term and short-term options, are in high demand. Patients, especially those with frequent attacks, seek preventive measures to reduce the severity and frequency of HAE episodes. On-demand treatments remain a crucial segment in the HAE therapeutics market, as they provide rapid relief during acute attacks.

Hereditary Angioedema Therapeutics Route of Administration Insights

The Market segmentation of Hereditary Angioedema Therapeutics based on route of administration includes intravenous, subcutaneous, oral. The intravenous segment dominated the market in 2022. Intravenous treatments remain a significant preference for HAE patients during severe attacks, ensuring rapid delivery of the medication. Subcutaneous options are gaining favour for prophylactic treatments, offering patients a more convenient and less invasive route of administration. The demand for oral medications is increasing, especially for patients seeking non-invasive prophylactic solutions.

Hereditary Angioedema Therapeutics Distribution Channel Insights

The Market segmentation of Hereditary Angioedema Therapeutics based on distribution channel includes hospital pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment dominated the market in 2022. Hospitals continue to be a key distribution channel, ensuring immediate access to HAE medications during emergencies. Retail pharmacies cater to the needs of patients seeking ongoing prescription refills and non-urgent medication supplies. The online pharmacy segment is witnessing substantial growth, driven by the convenience and accessibility it offers to HAE patients, particularly in remote areas.

Figure 2: Hereditary Angioedema Therapeutics Market, by distribution channel, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Hereditary Angioedema Therapeutics Products Regional Insights

By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North America Hereditary Angioedema Therapeutics market is expected to account for USD 1.4 billion in 2022 and is expected to exhibit an 14.12% CAGR during the study period. This is attributed to the market of Hereditary Angioedema therapeutics is well-established and witnesses continuous growth. This region boasts advanced healthcare facilities and high awareness of rare diseases like HAE. The demand for prophylactic treatments, especially long-term prophylaxis, remains significant, as patients prefer preventive measures to reduce the frequency and severity of attacks. 

The market also observes a growing preference for selective bradykinin B2 receptor antagonists, which offer oral alternatives for both prophylaxis and on-demand treatment. Intravenous administration is prevalent for immediate relief during acute attacks in the region further fuel the growth of the market. Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: Hereditary Angioedema Therapeutics Market share by region 2022 & 2032 (USD billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Hereditary Angioedema Therapeutics market is expected to account for the second-largest market share due to the rising research and development actvitity, rising product approval and favourable reimbursement policy for orphan drugs older population. Further, the Germany market of Hereditary Angioedema Therapeutics is expected to hold third place for the market share, and the UK market of Hereditary Angioedema Therapeutics is expected to fastest-growing market, and which is in the 4th place in the European region. Furthermore, France market of Hereditary Angioedema Therapeutics will hold the 5th place for the market share.

The Asia-Pacific Hereditary Angioedema Therapeutics market is expected to grow at a high growth rate from 2023 to 2032. This is due to the rising disposable income in the developing countries and availability of medical facility and medical staff,rising awareness programe launch. Moreover, China market of Hereditary Angioedema Therapeutics is expected to hold the largest market share, and the India market of Hereditary Angioedema Therapeutics is expected fastest-growing market in the Asia-Pacific region.

The Rest of the World includes the Middle East, Africa, and Latin America. Government initiatives to increase medical expenditure and increase healthcare infrastructure in the region contribute to the growth of the rest of the world market of Hereditary Angioedema Therapeutics.

Hereditary Angioedema Therapeutics Key Market Players & Competitive Insights

The presence of major market players in the Hereditary Angioedema Therapeutics Market is characterized by the presence of many international, regional, and local players. The companies are investing in R&D activities to expand their product portfolio for breast enhancement, which further drives the market growth of the Hereditary Angioedema Therapeutics. Moreover, the vendors compete based on cost, product quality, reliability, and aftermarket services and try to be the first to bring treatment for the public. It is crucial for the players to offer cost-efficient and high-quality products for Hereditary Angioedema Therapeutics to succeed in an intensely competitive market environment.

One of the primary business strategies adopted by manufacturers in the global Hereditary Angioedema Therapeutics industry to benefit clients and expand the market sector of Hereditary Angioedema Therapeutics is to manufacture locally to reduce operating costs.

Sanofi is a global life science company concentrating on improving access to healthcare and supporting the people throughout the continuum of care. From prevention to treatment, the company transforms scientific innovation into healthcare solutions in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. The company is present in more than 170 countries, and it has 37 manufacturing units in 36 countries.

Key Companies in the market of Hereditary Angioedema Therapeutics includes

• Takeda Pharmaceutical (Japan)


• CSL Behring (US)


• Sanofi (France)


• BioCryst Pharmaceuticals, Inc (US)


• Pharvaris B.V. (Switzerland)


• Ionis Pharmaceuticals, Inc (US)


• Pharming Group N.V. (Netherlands)


• KalVista Pharmaceuticals, Inc (US)


• IBio, Inc. (US)


• BioMarin Pharmaceutical Inc (US)

Hereditary Angioedema Therapeutics Industry Developments

February 2021 : KalVista (US) reported positive results in its Phase 2 clinical trial for KVD900 as an oral on-demand treatment for HAE attacks.

March 2023:Intellia Therapeutics, a US-based clinical-stage biotechnology company, launched an Investigational New Drug (IND) NTLA-2002, which was approved by the United States Food and Drug Administration for the treatment of hereditary angioedema.This enables the company’s ongoing Phase 1/2 trial to include the US in the worldwide Phase 2 part.

Hereditary Angioedema Therapeutics Market Segmentation

Hereditary Angioedema Therapeutics Type Outlook

• Type I


• Type II

Hereditary Angioedema Drug Class Outlook

• C1 Esterase Inhibitor


• Selective Bradykinin B2 Receptor Antagonist


• Kallikrein Inhibitor


• Others

Hereditary Angioedema Therapeutics Treatment Outlook

• Prophylaxis


• Long-term Prophylaxis


• Short-term Prophylaxis


• On-demand

Hereditary Angioedema Therapeutics Route of Administration Outlook

• Intravenous


• Subcutaneous


• Oral

Hereditary Angioedema Therapeutics Distribution Channel Outlook

• Hospital Pharmacy


• Retail Pharmacy


• Online Pharmacy

Hereditary Angioedema Therapeutics Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America